• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:郑丽云.双特异性抗体在结直肠癌治疗中的临床应用进展[J].中国现代应用药学,2024,41(19):113-112.
Zheng Liyun.Progress in clinical application of bispecific antibodies in colorectal cancer treatment[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(19):113-112.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 8次   下载 4 本文二维码信息
码上扫一扫!
分享到: 微信 更多
双特异性抗体在结直肠癌治疗中的临床应用进展
郑丽云
杭州市第一人民医院
摘要:
近十年来,结直肠癌(Colorectal cancer, CRC)的发病率持续上升,给个人和社会带来了沉重的负担。尽管靶向及免疫治疗显著改善了CRC患者的临床预后,但耐药性及免疫应答率低等问题阻碍了其整体治愈率的进一步提升。双特异性抗体(Bispecific antibody,BsAb)通过双靶点的设计有可能解决耐药及免疫应答的问题,成为近年来研究的热点。本文系统综述了目前用于CRC治疗的BsAb几种主要类型,并分述了BsAb的不同靶点及在CRC治疗中的临床应用进展。以期为后续用于CRC治疗的BsAb研究设计提供有益参考。
关键词:  双特异性抗体  结直肠癌  临床应用
DOI:
分类号:R284.1;R917.101??????
基金项目:
Progress in clinical application of bispecific antibodies in colorectal cancer treatment
Zheng Liyun1,2,3
1.Hangzhou First People'2.'3.s Hospital
Abstract:
The incidence of Colorectal cancer (CRC) is increasing in the decade, which has caused a serious burden for the individual and society. Although the targeted therapy and immunotherapy has significantly improved the clinical prognosis of CRC patients, the problems of drug resistance and low immune response rate hinder its further development of overall cure rate. Bispecific antibody (BsAb) as a hot field recently, and the problems of drug resistance and low immune response might be solved through the design of double targets. In this paper, several main types of BsAb used for CRC treatment at present are systematically reviewed, the different targets of BsAb and its clinical application progress in CRC treatment are discussed. Trying to provide useful reference for the subsequent research and design of BsAb for CRC treatment.
Key words:  bispecific antibody  colorectal cancer  clinical application
扫一扫关注本刊微信